ClinicalTrials.gg
CompletedNCT04356742Updated Mar 22, 2022

Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

A Phase 3 interventional study of Dapagliflozin 10mg and Placebo in Type 2 Diabetes, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-03-22.

Sponsored by Dong-A ST Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
57th of 180
198 · median 82
Started
2020
with 9 others
Phase 3
47 of 180
4 open now
Registered
136th of 180
by date
Lead sponsor
2 of 180
Dong-A ST Co., Ltd.

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 57th largest by enrollment, is one of 10 that started in 2020, is one of 47 in phase 3, and was the 136th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study evaluates the addition of dapagliflozin in the treatment of type 2 diabetes with metformin and evogliptin combination therapy. Half of subjects will receive dapagliflozin, metformin and evogliptin, while the other half will receive placebo, metformin and evogliptin.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with type II diabetes mellitus aged 19 years or older
  2. Patients who had taken metformin(≥1000mg/day) and DPP(dipeptidyl peptidase)-4 inhibitor combination therapy(or complex is allowed) at the same dose for at least 8 weeks prior to the screening visit
  3. Patients with fasting plasma glucose≤250mg/dL at the screening visit
  4. Patients with 18.5kg/m\^2≤≤40kg/m\^2 at the screening visit
  5. Patients who have signed an themselves after receiving detailed explanation about the clinical study

Exclusion criteria

Exclusion Criteria:

  1. Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic coma or -pre-coma, metabolic acidosis including lactic acidosis and diabetic ketoacidosis
  2. Patients with a medical history of (NYHA) class III\~IV heart failure or with congestive heart failure, acute and unstable heart failure
  3. Patients with severe infectious disease or severe traumatic systemic disorders
  4. Patients with hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction and other hypoxemia
  5. Patients with galactose intolerance, lapp lactase deficiency, glucose-galactose malabsorption
  6. Patients with moderate to severe stage renal disease, end stage renal disease, dialysis at the time of screening visit
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    Dapagliflozin 10mg + Evogliptin 5mg + Metformin

    Drug: Dapagliflozin 10mg · Drug: Evogliptin 5mg · Drug: Metformin≥1000mg

  • Placebo comparator
    Dapagliflozin Placebo + Evogliptin 5mg + Metformin

    Drug: Placebo · Drug: Evogliptin 5mg · Drug: Metformin≥1000mg

Interventions

  • Dapagliflozin 10mg, orally, once daily, up to 24weeks

    Also known as: Forxiga

  • DrugPlacebo

    Dapagliflozin Placebo, orally, once daily, up to 24weeks

  • Evogliptin 5mg, orally, once daily for background therapy

    Also known as: Suganon

  • DrugMetformin≥1000mg

    Metformin≥1000mg, orally, daily for background therapy

06

What researchers measure

Primary outcomes

  1. Change from the baseline in HbA1c (%) after 24 weeks

    Time frame: Baseline, 24 weeks

Secondary outcomes

  1. Change from the baseline in fasting plasma glucose(mg/dL) after 24 weeks

    Time frame: Baseline, 24 weeks

  2. Change from the baseline in HbA1c response rate(<7.0%, <6.5%) after 24 weeks

    Time frame: Baseline, 24 weeks

  3. Change from the baseline in weight after 24 weeks

    Time frame: Baseline, 24 weeks

07

Study locations

1 site
  • The Catholic University of Korea Bucheon St. Mary's Hospital
    Bucheon, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Feb 2022, 20 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2020
First posted
Apr 22, 2020
StartActual
May 26, 2020
Primary completionActual
Feb 23, 2022
CompletionActual
Feb 23, 2022
Last update
Mar 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04356742
Responsible party
Sponsor
First posted
Apr 22, 2020
Start date
May 26, 2020
Primary completion
Feb 23, 2022
Completion
Feb 23, 2022
Last update
Mar 22, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion